- Immutep’s (IMM) phase two Eftilagimod Alpha Treatment COVID (EAT COVID) study will soon advance to enrolment ahead of the randomised portion
- Up to 110 COVID-19 patients will participate in the study which undertaken at the University Hospital Pilsen in the Czech Republic
- Immutep will provide its lead product candidate, eftilagimod alpha, or efti, at no cost to the hospital
- In addition to their standard of care, the patients will receive three 10 milligram efti injections on three separate days
- The trial aimed at improving the patient’s immune response to prevent COVID-19 symptoms from getting worse
- Company shares are up 4.82 per cent and are trading at 43.5 cents
